Capsular hyaluronic acid in Pasteurella multocida type A and its counterpart in type D

Pandit, K.; Smith, Jessica

doi:10.1016/0034-5288(93)90005-z

Cited by 25 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P. multocida Carter type A (fowl cholera and pasteurellosis pathogen) makes a hyaluronan (HA) capsule (11). The capsules of type D (swine atrophic rhinitis pathogen) and type F (minor fowl cholera pathogen) are composed of unsulfated N-acetylheparosan (heparosan) or unsulfated chondroitin, respectively (5).…”

mentioning

confidence: 99%

Identification of a Distinct, Cryptic Heparosan Synthase from Pasteurella multocida Types A, D, and F

DeAngelis

White

2004

J Bacteriol

View full text Add to dashboard Cite

The extracellular polysaccharide capsules of Pasteurella multocida types A, D, and F are composed of hyaluronan, N-acetylheparosan (heparosan or unsulfated, unepimerized heparin), and unsulfated chondroitin, respectively. Previously, a type D heparosan synthase, a glycosyltransferase that forms the repeating disaccharide heparosan backbone, was identified. Here, a ϳ73% identical gene product that is encoded outside of the capsule biosynthesis locus was also shown to be a functional heparosan synthase. Unlike PmHS1, the PmHS2 enzyme was not stimulated greatly by the addition of an exogenous polymer acceptor and yielded smallermolecular-weight-product size distributions. Virtually identical hssB genes are found in most type A, D, and F isolates. The occurrence of multiple polysaccharide synthases in a single strain invokes the potential for capsular variation.

show abstract

mentioning

confidence: 99%

Identification of a Distinct, Cryptic Heparosan Synthase from Pasteurella multocida Types A, D, and F

DeAngelis

White

2004

J Bacteriol

View full text Add to dashboard Cite

show abstract

“…Since Carter & Annau in 1953, hyaluronic acid has been recognized as an major capsule component in some strains of P. multocida. Later investigations have shown that serovar A capsules nearly always contain hyaluronic acid (Carter, 1972;Pandit & Smith, 1993), whereas it has not been detected in serovars B and E (Bain et al, 1982). Many serovar D strains have been shown to contain a yet unidentified capsule component which shows many similar properties to hyaluronic acid (Pandit & Smith, 1993).…”

Section: Capsule and Somatic Antigensmentioning

confidence: 99%

“…Later investigations have shown that serovar A capsules nearly always contain hyaluronic acid (Carter, 1972;Pandit & Smith, 1993), whereas it has not been detected in serovars B and E (Bain et al, 1982). Many serovar D strains have been shown to contain a yet unidentified capsule component which shows many similar properties to hyaluronic acid (Pandit & Smith, 1993). Hyaluronic acid appears to be responsible for most of the suggested virulence properties of the capsule.…”

Section: Capsule and Somatic Antigensmentioning

confidence: 99%

“…In general, hyaluronic acid is believed to influence the physical properties of the capsule and probably prevents opsonisation or phagocytosis by phagocytic cells, perhaps by mimicking host antigens, since the acid is naturally present in the host tissues (Anderson et al, 1984] Chanter 1990Harmon et al, 1991;Maheswaran & Thies, 1979;Pandit & Smith, 1993).…”

Section: Capsule and Somatic Antigensmentioning

confidence: 99%

See 1 more Smart Citation

Avian pasteurellosis: Taxonomy of the organisms involved and aspects of pathogenesis

Christensen

Bisgaard

1997

Avian Pathology

View full text Add to dashboard Cite

“…The capsule of P. multocida type A is most often associated with avian cholera, and functions as a virulence factor, and it is composed largely of hyaluronic acid [1,2]. Strains belonging to capsular types B, D and F of P. multocida have also been isolated from diseased birds, but with low incidence as compared to capsular type A [3,4].…”

Section: Introductionmentioning

confidence: 99%

Construction and Characterization of an Acapsular Mutant of Pasteurella multocida Strain P-1059 (A:3)

Zhang¹

2013

J Vaccines Vaccin

View full text Add to dashboard Cite

To further investigate the role of capsule involved in virulence of Pasteurella multocida P-1059 (A:3), a hexB deleted mutant was constructed by homologous recombination. The DNA replacement was confirmed by PCR, Reverse transcription (RT)-PCR and DNA sequencing. Experiments were conducted to compare the differences of biological characteristics such as capsular structure, capsular polysaccharide content, virulence and serum resistance between the hexB deleted mutant of ∆hexB and wild-type strain P-1059, as well as the complemented strain P-1059C. And the ability of the acapsular mutant ∆hexB to induced protection against wild-type challenge in chickens. Electron microscopy examination of the ∆hexB showed the absence of capsular material compared to the P-1059 and P-1059C. The ∆hexB was sensitive to the bactericidal action of chicken serum, whereas the P-1059 and P-1059C were both resistant. The ∆hexB was highly attenuated in chickens by intravenously injection, and intramuscular administration of ∆hexB to chickens stimulated significant protection against P-1059 and the homologous strain X-73(A:1). These results demonstrated that the capsule is a major virulence factor of Pasteurella multocida serotype A:3 strains.

show abstract

Capsular hyaluronic acid in Pasteurella multocida type A and its counterpart in type D

Cited by 25 publications

References 16 publications

Identification of a Distinct, Cryptic Heparosan Synthase from Pasteurella multocida Types A, D, and F

Identification of a Distinct, Cryptic Heparosan Synthase from Pasteurella multocida Types A, D, and F

Avian pasteurellosis: Taxonomy of the organisms involved and aspects of pathogenesis

Construction and Characterization of an Acapsular Mutant of Pasteurella multocida Strain P-1059 (A:3)

Contact Info

Product

Resources

About